NASDAQ: ATOSAtossa Therapeutics Inc Stock
$2.35-0.01 (-0.42%)
Updated Aug 12, 2026
ATOS Price
$2.35
Fair Value Price
$4.80
Market Cap
$23.45M
52 Week Low
$1.70
52 Week High
$19.35
P/E
-0.53x
P/B
0.87x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$37.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.2
Operating Cash Flow
-$36M
Beta
1.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ATOS Overview
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATOS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATOS
Ranked#380 of 466
Ranked#380 of 466
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.90 | A | |
| $112.18 | A | |
| $10.98 | A |
Be the first to know about important ATOS news, forecast changes, insider trades & much more!
ATOS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATOS ($2.35) is undervalued by 51% relative to our estimate of its Fair Value price of $4.80 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ATOS ($2.35) is significantly undervalued by 51% relative to our estimate of its Fair Value price of $4.80 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ATOS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATOS due diligence checks available for Premium users.
Valuation
ATOS fair value
Fair Value of ATOS stock based on Discounted Cash Flow (DCF)
Price
$2.35
Fair Value
$4.80
Undervalued by
51.00%
ATOS ($2.35) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATOS ($2.35) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATOS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATOS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.53x
Industry
15.75x
Market
14.4x
ATOS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.87x
Industry
5.8x
ATOS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATOS's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.5M
Profit Margin
0%
ATOS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$32.3M
Liabilities
$5.5M
Debt to equity
0.2
ATOS's short-term assets ($31.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATOS's short-term assets ($31.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATOS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ATOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.6M
Investing
$0.0
Financing
$4.0M
ATOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATOS vs Biotech Stocks
Atossa Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.